• Moderna dosed the first U.S. participant in a Phase 1 trial of mRNA-4200, an off-the-shelf tumor-targeted cancer antigen therapy for solid tumors.
• Study will assess safety and tolerability of mRNA-4200 given with checkpoint inhibitor therapy in adults with advanced or metastatic solid tumors.
• mRNA-4200 encodes seven shared tumor antigens, aiming to induce and expand T-cell responses across multiple tumor types.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607160700ACCESSWRNAPR_____1190971) on July 16, 2026, and is solely responsible for the information contained therein.